Accelerating research
and development of
new antibiotics and
alternatives
The Netherlands Antibiotic Development Platform
The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.
NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.
Stay informed on NADP and subscribe to our Update.
NADP Vouchers
An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.
These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.
Latest News
New ReAct Report: When the Drugs Don’t Work – Antibiotic Resistance as a Global Development Problem
Working antibiotics have given us a huge boost in quality of life over the last nine decades, but their importance and value is overlooked. Antibiotics play a crucial role in many more areas of life than most people imagine. This new report by ReAct and Dag Hammarskjöld Foundation looks at the state of global development...
Romanian EU Presidency aims to strengthen Europe’s One Health approach to fighting antimicrobial resistance
Antimicrobial resistance (AMR) is widely recognized as one of the 21st century’s greatest threats to health, welfare and food security. Worldwide, an estimated 700 000 people die each year from drug-resistant infections. In the European Union (EU) and European Economic Area (EEA) alone, 33 000 lives are claimed each year, and these numbers are rising.
Madam Therapeutics has been awarded a grant from the Netherlands Antibiotic Development Platform (NADP)
Madam Therapeutics announced that it is one of the four companies in the Netherlands that have been awarded a novel grant from the Netherlands Antibiotic Development Platform (NADP).
NADP Partners
Supported by
NADP Partners
Supported by